Healthcare Realty Trust Inc
For the period ended Sep 30, 2025. Filed Oct 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 31, 2025
HR$19.35-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2025 and 2024
Amounts in thousands
| OPERATING ACTIVITIES | ||
|---|---|---|
| NINE MONTHS ENDEDSeptember 30, | ||
| 2025 | 2024 | |
| Net loss | $(264,076) | $(555,692) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 436,558 | 514,821 |
| Other amortization | 35,487 | 35,051 |
| Share-based compensation | 19,035 | 14,852 |
| Amortization of straight-line rent receivable (lessor) | (22,354) | (20,935) |
| Amortization of straight-line rent on operating leases (lessee) | 2,566 | 2,963 |
| Gain on sales of real estate properties and other assets | (99,678) | (77,670) |
| Loss on extinguishment of debt | 286 | — |
| Loss on derivatives | 2,844 | — |
| Impairment of real estate properties and credit loss reserves | 258,791 | 232,450 |
| Impairment of goodwill | — | 250,530 |
| Equity (income) loss from unconsolidated joint ventures | (446) | 360 |
| Distributions from unconsolidated joint ventures | 16,487 | 4,946 |
| Non-cash interest from financing and notes receivable | (657) | (1,610) |
| Changes in operating assets and liabilities: | ||
| Other assets, including right-of-use-assets | (26,035) | (5,758) |
| Accounts payable and accrued liabilities | (32,993) | (27,925) |
| Other liabilities | (1,059) | (2,778) |
| Net cash provided by operating activities | 324,756 | 363,605 |
| INVESTING ACTIVITIES | ||
| Development of real estate | (12,605) | (51,336) |
| Additional long-lived assets | (243,605) | (186,742) |
| Funding of mortgages and notes receivable | (6,027) | (3,565) |
| Investments in unconsolidated joint ventures | (1,546) | — |
| Investment in financing receivable | (497) | (22) |
| Contributions from redeemable non-controlling interests | — | 13 |
| Proceeds from sales of real estate properties and additional long-lived assets | 393,111 | 722,940 |
| Proceeds from insurance recovery | 2,000 | — |
| Proceeds from notes receivable repayments | 53,513 | 861 |
| Net cash provided by investing activities | 184,344 | 482,149 |
| FINANCING ACTIVITIES | ||
| Borrowings on unsecured credit facility | 831,000 | 1,081,000 |
| Repayments on unsecured credit facility | (682,000) | (875,000) |
| Repayment on term loans | (108,532) | (250,000) |
| Repayments of notes and bonds payable | (251,042) | (25,130) |
| Dividends paid | (302,528) | (348,064) |
| Net proceeds from issuance of common stock | — | 104 |
| Common stock redemptions | (3,628) | (321) |
| Common stock repurchases | — | (423,070) |
| Distributions to non-controlling interest holders | (3,884) | (3,612) |
| Redemption of non-controlling interest | (677) | (625) |
| Debt issuance and assumption costs | (13,083) | (563) |
| Payments made on finance leases | (145) | (13) |
| Net cash used in financing activities | (534,519) | (845,294) |
| (Decrease) increase in cash and cash equivalents | (25,419) | 460 |
|---|---|---|
| Cash and cash equivalents at beginning of period | 68,916 | 25,699 |
| Cash and cash equivalents at end of period, including held for sale | 43,497 | 26,159 |
| Cash and cash equivalents held for sale | (152) | (3,358) |
| Cash and cash equivalents at end of period | $43,345 | $22,801 |
| Supplemental Cash Flow Information | NINE MONTHS ENDEDSeptember 30, | |
| 2025 | 2024 | |
| Interest paid | $160,215 | $177,507 |
| Mortgage notes receivable taken in connection with sale of real estate | $5,400 | $— |
| Invoices accrued for construction, tenant improvements and other capitalized costs | $42,711 | $49,886 |
| Capitalized interest | $8,591 | $3,211 |
| Proceeds from dispositions held in escrow | $56,915 | $— |
| Contribution of real estate properties into unconsolidated joint venture | $— | $110,879 |
The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, are an integral part of these financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.